Literature DB >> 19391103

Concepts in in vivo siRNA delivery for cancer therapy.

Christopher S Gondi1, Jasti S Rao.   

Abstract

In vivo gene silencing using RNAi plays an important role in target validation and is advancing towards the development of RNAi-based therapeutics. RNAs were thought to have just two broad functions in cells as messenger RNAs (mRNAs) and ribosomal RNAs, but recently the relevance of microRNAs is becoming more clearly understood. mRNA molecules transmit information between DNA and protein and, as such, are vital intermediaries for gene expression. Ribosomal and transfer RNAs have structural, catalytic, and information-decoding roles in the process of protein synthesis, whereas microRNAs are regulators of gene expression. This review presents the early and intriguing successes of using siRNAs for in vivo gene silencing and its use as a possible cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19391103      PMCID: PMC2692765          DOI: 10.1002/jcp.21790

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  95 in total

Review 1.  Gene therapy progress and prospects: hydrodynamic gene delivery.

Authors:  H Herweijer; J A Wolff
Journal:  Gene Ther       Date:  2006-11-30       Impact factor: 5.250

Review 2.  Polymeric core-shell nanoparticles for therapeutics.

Authors:  Yi-Yan Yang; Yong Wang; Ross Powell; Peggy Chan
Journal:  Clin Exp Pharmacol Physiol       Date:  2006 May-Jun       Impact factor: 2.557

Review 3.  Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.

Authors:  Shyh-Dar Li; Leaf Huang
Journal:  Curr Opin Investig Drugs       Date:  2008-12

4.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Authors:  Udit N Verma; Rama M Surabhi; Aurelia Schmaltieg; Carlos Becerra; Richard B Gaynor
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

5.  Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Authors:  Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

6.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.

Authors:  Sebastien Spagnou; Andrew D Miller; Michael Keller
Journal:  Biochemistry       Date:  2004-10-26       Impact factor: 3.162

Review 7.  Therapeutic potential of RNA interference against cancer.

Authors:  Fumitaka Takeshita; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2006-08       Impact factor: 6.716

8.  Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.

Authors:  Chun-Fang Xia; Ruben J Boado; William M Pardridge
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 9.  Advances in the development of siRNA-based therapeutics for cancer.

Authors:  Yu Shen
Journal:  IDrugs       Date:  2008-08

10.  Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

View more
  19 in total

Review 1.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

Review 2.  Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.

Authors:  David Karnak; Liang Xu
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

3.  Kinetics and Mechanisms of Oxidative Cleavage of HIV RRE RNA by Rev-Coupled Transition Metal Chelates.

Authors:  Jeff C Joyner; Kevin D Keuper; J A Cowan
Journal:  Chem Sci       Date:  2013-04-01       Impact factor: 9.825

4.  A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma.

Authors:  Carl-Jørgen Arum; Yosuke Kodama; Natale Rolim; Marius Widerøe; Endre Anderssen; Trond Viset; Marit Otterlei; Steinar Lundgren; Duan Chen; Chun-Mei Zhao
Journal:  World J Urol       Date:  2010-04-08       Impact factor: 4.226

5.  Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.

Authors:  Y Tian; B Guo; H Jia; K Ji; Y Sun; Y Li; T Zhao; L Gao; Y Meng; D V Kalvakolanu; D J Kopecko; X Zhao; L Zhang; D Xu
Journal:  Cancer Gene Ther       Date:  2012-05-04       Impact factor: 5.987

Review 6.  MicroRNAs as biomarkers in colorectal cancer.

Authors:  Kristina Schee; Øystein Fodstad; Kjersti Flatmark
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

7.  Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.

Authors:  Pamela Zengel; Diana Ramp; Brigitte Mack; Stefan Zahler; Alexander Berghaus; Bernd Muehlenweg; Olivier Gires; Suna Schmitz
Journal:  BMC Cancer       Date:  2010-03-11       Impact factor: 4.430

8.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

9.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

Review 10.  Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.

Authors:  Sarah M Eck; Jessica S Blackburn; Adam C Schmucker; Peter S Burrage; Constance E Brinckerhoff
Journal:  J Autoimmun       Date:  2009-10-01       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.